Pretreatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients With In flammatory Bowel Diseases

被引:100
作者
Kochar, Bharati [1 ,2 ]
Cai, Winston [1 ]
Cagan, Andrew [3 ]
Ananthakrishnan, Ashwin N. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA
[2] Mongan Inst, Clin Translat Epidemiol Unit, Boston, MA USA
[3] Partners Healthcare, Boston, MA USA
关键词
Immunosuppression; Side Effect; Thiopurine; Aging; CROHNS-DISEASE; ULCERATIVE-COLITIS; OPPORTUNISTIC INFECTIONS; SERIOUS INFECTIONS; OLDER-ONSET; MORTALITY; MORBIDITY; HOSPITALIZATION; POPULATION; INFLIXIMAB;
D O I
10.1053/j.gastro.2020.02.032
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Infections are an important adverse effect of immunosuppression for treatment of inflammatory bowel diseases (IBDs). However, risk of infection cannot be sufficiently determined based on patients' ages or comorbidities. Frailty has been associated with outcomes of patients with other inflammatory diseases. We aimed to determine the association between frailty and risk of infections after immunosuppression for IBD. METHODS: We performed a cohort study of 11,001 patients with IBD, using a validated frailty definition based on International Classification of Disease codes to identify patients who were frail vs fit in the 2 years before initiation of an anti-tumor necrosis factor (TNF) or immunomodulator therapy, from 1996 through 2010. Our primary outcome was an infection in the first year after treatment. We constructed multivariable logistic regression models, adjusting for clinically pertinent confounders (age, comorbidities, steroid use, and combination therapy) to determine the association between frailty and posttreatment infections. RESULTS: There were 1299 patients treated with an anti-TNF agent and 2676 patients treated with an immunomodulator. In this cohort, 5% of patients who received anti-TNF therapy and 7% of patients who received an immunomodulator were frail in the 2 years before immunosuppression. Frail patients were older and had more comorbidities. Higher proportions of frail patients developed infections after treatment (19% after TNF and 17% after immunomodulators) compared with fit patients (9% after TNF and 7% after immunomodulators; P < .01 for frail vs fit in both groups). Frail patients had an increased risk of infection after we adjusted for age, comorbidities, and concomitant medications (anti-TNF adjusted odds ratio, 2.05 [95% confidence interval, 1.07-3.93] and immunomodulator adjusted odds ratio, 1.81 [95% confidence interval, 1.22-2.70]). CONCLUSIONS: Frailty was associated with infections after immunosuppression in patients with IBD after we adjust for age and comorbidities. Systematic assessment and strategies to improve frailty might reduce infection risk in patients with IBD.
引用
收藏
页码:2104 / +
页数:10
相关论文
共 42 条
[1]   Safety Profile of IBD Therapeutics: Infectious Risks [J].
Afif, Waqqas ;
Loftus, Edward V., Jr. .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2009, 38 (04) :691-+
[2]   Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases [J].
Ananthakrishnan, A. N. ;
Cagan, A. ;
Cai, T. ;
Gainer, V. S. ;
Shaw, S. Y. ;
Churchill, S. ;
Karlson, E. W. ;
Murphy, S. N. ;
Kohane, I. ;
Liao, K. P. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (11) :1141-1148
[3]   Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities [J].
Ananthakrishnan, Ashwin N. ;
Donaldson, Tamara ;
Lasch, Karen ;
Yajnik, Vijay .
INFLAMMATORY BOWEL DISEASES, 2017, 23 (06) :882-893
[4]   Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease [J].
Ananthakrishnan, Ashwin N. ;
Shi, Hai Yun ;
Tang, Whitney ;
Law, Cindy C. Y. ;
Sung, Joseph J. Y. ;
Chan, Francis K. L. ;
Ng, Siew C. .
JOURNAL OF CROHNS & COLITIS, 2016, 10 (10) :1224-1236
[5]   Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis [J].
Ananthakrishnan, Ashwin N. ;
Cagan, Andrew ;
Cai, Tianxi ;
Gainer, Vivian S. ;
Shaw, Stanley Y. ;
Savova, Guergana ;
Churchill, Susanne ;
Karlson, Elizabeth W. ;
Kohane, Isaac ;
Liao, Katherine P. ;
Murphy, Shawn N. .
INFLAMMATORY BOWEL DISEASES, 2016, 22 (04) :880-885
[6]   Colonoscopy Is Associated With a Reduced Risk for Colon Cancer and Mortality in Patients With Inflammatory Bowel Diseases [J].
Ananthakrishnan, Ashwin N. ;
Cagan, Andrew ;
Cai, Tianxi ;
Gainer, Vivian S. ;
Shaw, Stanley Y. ;
Churchill, Susanne ;
Karlson, Elizabeth W. ;
Murphy, Shawn N. ;
Kohane, Isaac ;
Liao, Katherine P. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (02) :322-U163
[7]   Improving Case Definition of Crohn's Disease and Ulcerative Colitis in Electronic Medical Records Using Natural Language Processing: A Novel Informatics Approach [J].
Ananthakrishnan, Ashwin N. ;
Cai, Tianxi ;
Savova, Guergana ;
Cheng, Su-Chun ;
Chen, Pei ;
Perez, Raul Guzman ;
Gainer, Vivian S. ;
Murphy, Shawn N. ;
Szolovits, Peter ;
Xia, Zongqi ;
Shaw, Stanley ;
Churchill, Susanne ;
Karlson, Elizabeth W. ;
Kohane, Isaac ;
Plenge, Robert M. ;
Liao, Katherine P. .
INFLAMMATORY BOWEL DISEASES, 2013, 19 (07) :1411-1420
[8]   Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases [J].
Ananthakrishnan, Ashwin N. ;
McGinley, Emily L. .
JOURNAL OF CROHNS & COLITIS, 2013, 7 (02) :107-112
[9]   Thymic involution in aging [J].
Aspinall, R ;
Andrew, D .
JOURNAL OF CLINICAL IMMUNOLOGY, 2000, 20 (04) :250-256
[10]   Risk Factors Associated with Clostridium difficile Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis [J].
Balram, Bhairavi ;
Battat, Robert ;
Al-Khoury, Alex ;
D'Aoust, Julie ;
Afif, Waqqas ;
Bitton, Alain ;
Lakatos, Peter L. ;
Bessissow, Talat .
JOURNAL OF CROHNS & COLITIS, 2019, 13 (01) :27-38